Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Creo Medical GroupLSE:CREO 52 3-Year RORE % is -57.14 as of Dec. 2025. GuruFocus rates LSE:CREO with a GF Score™ of 52/100 and a GF Value™ of £0.18 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 777 Medical Devices & Instruments companies, Creo Medical Group ranks worse than 84.3% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Creo Medical Group's 3-Year RORE % for the quarter that ended in Dec. 2025 was -57.14%.
The industry rank for Creo Medical Group's 3-Year RORE % or its related term are showing as below:
LSE:CREO's 3-Year RORE % is ranked worse than 84.3% of 777
companies
in the Medical Devices & Instruments industry
Industry Median: -4.03
vs LSE:CREO: -57.14
Creo Medical Group (LSE:CREO) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Creo Medical Group 3-Year RORE % Related Terms
Creo Medical Group 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Creo Medical Group's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:CREO vs ABT, SYK, MDT: 3-Year RORE % Comparison
For the Medical Devices subindustry, Creo Medical Group's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Creo Medical Group 3-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Creo Medical Group's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Creo Medical Group's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.
Creo Medical Group (LSE:CREO) has a 3-Year RORE % of -57.14 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Creo Medical Group and its competitors. According to the industry distribution chart, Creo Medical Group ranks #655 out of 777 companies in the Medical Devices & Instruments industry, placing it in the top 84.3%.
Is Creo Medical Group's 3-Year RORE % too high?
Creo Medical Group's current 3-Year RORE % is -57.14. Based on the distribution chart, Creo Medical Group ranks #655 out of 777 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Creo Medical Group has a GF Score™ of 52/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Creo Medical Group's 3-Year RORE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Creo Medical Group ranks #655 out of 777 companies for 3-Year RORE %. This places Creo Medical Group in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Creo Medical Group and its competitors. Creo Medical Group's current 3-Year RORE % is -57.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Creo Medical Group stock overvalued right now?
Based on GuruFocus' analysis, Creo Medical Group (LSE:CREO) is currently considered Modestly Undervalued. The stock's GF Value™ is £0.18, compared to a current price of £0.14 — trading 20.8% below its estimated fair value. The current 3-Year RORE % is -57.14. Creo Medical Group's overall GF Score™ is 52/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Creo Medical Group (LSE:CREO), the current 3-Year RORE % is -57.14 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Creo Medical Group (LSE:CREO) Overvalued in 2026?
Based on GuruFocus' analysis, Creo Medical Group stock appears to be undervalued.
The current stock price of £0.14 is trading 20.8% below its estimated GF Value™ of £0.18.
GuruFocus considers Creo Medical Group to be Modestly Undervalued.
Key valuation signals for LSE:CREO:
3-Year RORE %: -57.14
GF Value™: £0.18 vs. price of £0.14 (20.8% below fair value)
No single metric tells the full story. See the LSE:CREO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called Croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. The reportable segment of the company is the research and development of electrosurgical medical devices relating to the field of surgical endoscopy. Geographically, the company generates a majority of its revenue from United Kingdom and the rest from Europe and the rest of the world.
52GF Score
Get the complete analysis for LSE:CREO
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:CREO has been successfully added to your 
